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Abstract
The Editorial Board of Journal of Translational Medicine is pleased to announce a prize to recognize
outstanding contributions in the field of translational medicine. The prize is sponsored by Pfizer
Global Research and Development, Global Translational Medicine and supported by the Journal of
Translational Medicine Editorial Board.
Rewarding clinically-relevant, evidence-based 
research
It has been almost three years since we launched the Jour-
nal of Translational Medicine on July 24th, 2003 [1] as an
open access journal devoted to the appropriate peer
review and rapid publication of results generated by clin-
ical investigations. The uniqueness of the Journal resides
in the major, if not exclusive emphasis on translational
medicine. This strategy stems from the realization that we
have to satisfy two needs in order for translational medi-
cine to flourish. First, it is widely acknowledged that
results obtained in animal model systems, although a very
valuable source of information, are only rarely super-
imposable to those obtained in an clinical setting, even
following genetic manipulation of animal models. This
realization has provided the impetus to implement clini-
cal investigations in order to assess the clinical relevance
of information derived from in vitro studies and from ani-
mal models. This approach has been possible thanks to
the major recent technological progress which has facili-
tated the application of basic research to address clinically
relevant questions in a clinical setting. Second, the general
realization of the difficulties for journals with emphasis
on basic research to accommodate translational medicine
papers has provided the rationale for the development of
a forum fully dedicated to translational medicine.
The launch and successful development of the Journal of
Translational Medicine has been possible thanks to the
enthusiastic participation of investigators who have sub-
mitted manuscripts to the journal and to the active partic-
ipation of a specialized Editorial Board and investigators
with expertise in the clinical and the basic aspects of sci-
ence.
The journal has received enthusiastic international sup-
port and has been rapidly recognized and tracked by
PubMed, PubMed Central, Thomson Scientific (ISI), Sco-
pus and Embase. Together with high quality research arti-
cles, we have received and published several important
contributions [2-11] related to the obstacles and opportu-
nities encountered when applying the emerging discipline
of Translational Medicine. We strongly encourage our col-
leagues to continue this important dialogue since it helps
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us to sharpen and adjust the directions of the journal to
the evolving changes in translational medicine.
To stimulate research in translational medicine and to
enhance the submission of high quality manuscripts the
journal is establishing a prize, "The Excellence Award in
Translational Medicine," with the purpose of rewarding
efforts to link science to bedside care. The prize is spon-
sored by Pfizer Global Research and Development, Global
Translational Medicine, and supported by the Journal of
Translational Medicine Editorial Board.
Although we recognize the importance and positive
impact of commentaries and review articles on the devel-
opment of translational medicine, only articles including
original data will be considered for the award.
The Excellence in Translational Medicine Award
The recipient of The Excellence in Translational Medicine
Award will receive a $2,500 prize to cover the expenses for
any meeting sponsored by a non-for-profit organization
that is relevant to the goal of translational medicine/
research. Submitted articles will be evaluated with regard
to: relevance to the purposes of translational medicine/
research translating new ideas into patient care (bench to
bedside) and/or discovery-driven, evidence-based studies
aimed at understanding human pathology by the direct
study of human subjects (bedside to bench). Selection cri-
teria will include scientific merit, sound research design,
rigorous methodology, originality and clarity.
Eligibility criteria and selection process
• The award will be granted to the first author of a
Research or Methodology manuscript containing original
data published in the Journal of Translational Medicine
between July 1st 2006 and June 30th 2007.
• Candidates may be self nominated or nominated by a
colleague.
• Candidates must be the primary clinician or investigator
involved in the project described by the article. If there are
multiple first authors, each first author of the selected
manuscript may claim designation as a candidate. In the
event of multiple authors sharing the award, the prize will
be divided equally. If there are multiple first authors, this
must be indicated at the time of submission.
• Authors from laboratories of the members of the selec-
tion committee are not eligible for the Award.
Evaluation criteria
Submitted articles will be evaluated with regard to:
• Relevance to the purposes of translational medicine/
research translating new ideas into patient care (bench to
bedside) and/or discovery-driven, evidence-based studies
aimed at the understanding of human pathology by the
direct study of human subjects (bedside to bench)
• Scientific merit
• Sound research design
• Rigorous methodology
• Originality
• Clarity
How to apply
All applications should be made via the online applica-
tion form. Candidates may be self-nominated, or nomi-
nated by others. Nominations must be received between
July 1st 2006 and June 30th 2007.
• Online application form: http://www.translational-
medicine.com/info/about/award.asp
Selection committee
Selection will be made by a committee of members of the
Editorial Board chaired by Prof Richard J. Ablin, Univer-
sity of Arizona, Tucson, AZ, USA and Prof Yi-Xin Zen, Sun
Yat-sen University Cancer Center, Guangzhou, China.
We hope the Excellence in Translational Medicine Award
will contribute, together with other initiatives, to encour-
age and reward those investigators who are devoted to
improving the efficiency in which biomedical research is
performed with the ultimate goal of preventing disease.
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